WINNIPEG, MANITOBA--(Marketwire - Aug. 13, 2012) - Miraculins Inc., (MOM.V) a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today an agreement with London Drugs, one of Canada's leading pharmacy chains, and Pear Healthcare Solutions, that will see the retail pharmacy launch of its PreVu(R) Non-Invasive Skin Cholesterol Point of Care (POC) Test take place in up to ten London Drugs locations in Vancouver and the Lower Mainland, planned for October 2012. "This pilot program is a very significant milestone for PreVu in Canada, as well as a major step forward in the commercialization of the technology worldwide," said Paul Moreau, Vice President, Sales and Marketing for Miraculins Inc. "We are very pleased that London Drugs, a highly respected retail brand in the healthcare services sector, wants to make the PreVu POC Test available to its customers to help them better understand their risk of coronary artery disease (CAD). With over 70,000 heart attacks in Canada each year, resulting in over 16,000 deaths, this pilot program represents an important development towards realizing better heart health for all Canadians at risk." As part of the agreement, London Drugs will … Continue reading →

A coronial inquest is investigating whether a mix of prescription drugs and marijuana caused the death of a Perth woman. Linda Mulvaney, 54, regularly smoked marijuana and took her husband's painkillers on top of her own medication to help suppress the agony she experienced from prolonged migraines and lower back and shoulder pain, the inquest was told. They said 'we don't have bed space for people with headaches. She died on June 17, 2008, from multi-organ failure which may have been caused by respiratory depression from sedating drugs. The inquest also is examining whether her husband's delay in seeking medical help two days after she fell into a semi-coma contributed to her death. Advertisement Mrs Mulvaney had long experienced migraines as a result of a childhood car accident. Later in life, their duration increased from two to three days to weeks. She would usually sleep through much of the episode, only waking to drink water and smoke cigarettes, her husband Tony Mulvaney told the inquest. In the two years leading up to her death, she increasingly suffered hallucinations and would do "silly things" such as going outside naked and asking the neighbours to cook Mr Mulvaney's dinner. Mr Mulvaney said … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/rs7g34/global_breast_canc) has announced the addition of the "Global Breast Cancer Drugs Market 2011-2015" report to their offering. One of the key factors contributing to this market growth is the increasing prevalence of breast cancer worldwide. The Global Breast Cancer Drugs market has also been witnessing the trend of the emergence of combination therapies to treat breast cancer effectively. However, the availability of alternative treatment methods could pose a challenge to the growth of this market. Key vendors dominating this market space include AstraZeneca plc, Novartis, Roche Pharmaceuticals, and Sanofi S.A. Other vendors mentioned in the report: Eli Lilly and Co. and GlaxoSmithKline plc. Commenting on the report, an analyst from TechNavio's Healthcare team said; The current trend witnessed by the Global Breast Cancer Drugs market is combination therapy being used to treat breast cancer. Many oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites in the body can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying … Continue reading →

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/wdfpps/global_hyperphosph) has announced the addition of the "Global Hyperphosphatemia Drugs Market 2011-2015" report to their offering. TechNavio launched its report Global Hyperphosphatemia Drugs Market 2011-2015 based on an in-depth study covering the Americas, and the EMEA and APAC regions. The report aims to aid decision makers' understanding of the present and future landscape of the market. Commenting on the report, an analyst from TechNavio's Healthcare team said; The Global Hyperphosphatemia Drugs market provides enough growth opportunity for vendors because of the increasing demand for phosphate binders in chronic kidney disease (CKD) and hyperphosphatemia treatments. Since iron-based phosphate binders have better phosphate-binding capacity, vendors in the market are investing heavily in R&D to develop iron-based phosphate binders for the treatment of hyperphosphatemia in end-stage renal disease patients. According to the report, there is an increase in the prevalence of CKD across the world, and CKD is one of the main causes of hyperphosphatemia. Thus, the increasing prevalence of kidney diseases will drive the Global Hyperphosphatemia Drugs market. Further, the report also discusses that the biggest challenge that the Global Hyperphosphatemia Drugs market is facing is the side effects caused by currently used phosphate binders. The study … Continue reading →